SecBot SecBot
8-K ·Filed Nov 5, 2026

PHIO

Phio Pharmaceuticals Corp.
BEARISH
Impact 5/10
Horizonweeks Processed11d 10h ago SEC0001437749-26-035277
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The FDA response on the Phase 2b study design, expected by end of November 2026, is the next major catalyst. Cash runway appears tight given the $10.6M balance and rising R&D spend; watch for potential equity financing or partnership announcements to extend runway beyond early 2027.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.8013
T+0 close · Nov 5, 2026 · via day close
Latest settled
−3.78%
T+5 · $0.7710 · next T+20 in 20d
Vs SPY
−6.38%
α at T+5
Latest observation
−5.93%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $0.8013entry
  2. T+1 · 8d ago +4.82%α +2.45% · $0.8399
  3. T+5 · 4d ago −3.78%α −6.38% · $0.7710
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Phio Pharmaceuticals reported Q3 2026 results with a net loss of $4.2M, wider than the $2.4M loss a year ago, driven by higher R&D spending on the PH-762 program. The company completed commercial-scale cGMP manufacturing and submitted a final Phase 1b clinical study report to the FDA, with a response expected by end of November 2026. Cash burn remains high, with cash dropping to $10.6M from $21.0M at year-end 2025, raising financing concerns.

Key Facts

  • Net loss of $4.2M for Q3 2026 vs $2.4M in Q3 2025, a 74% increase
  • Cash and cash equivalents fell to $10.6M as of Sep 30, 2026 from $21.0M at Dec 31, 2025
  • R&D expenses rose 159% to $3.0M in Q3 2026, driven by PH-762 program costs
  • Final Phase 1b clinical study report submitted to FDA; response expected by end of November 2026
  • First commercial-scale cGMP batch of PH-762 drug substance completed; Phase 2b initiation targeted for Q1 2027
  • No revenue reported; company is a clinical-stage biotech with no approved products

Financial Impact

Net loss of $4.2M in Q3 2026, cash burn of $10.4M over nine months; cash runway likely limited given $10.6M remaining and rising R&D costs

cashnet lossR&D expenses

Risk Factors

  • Cash burn rate is high; $10.6M may not fund operations into H2 2027 without additional financing
  • No approved products or revenue; clinical-stage biotech with binary FDA outcome risk
  • Potential dilutive equity financing needed if FDA feedback delays Phase 2b or requires additional studies

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-035277
Document: phio20261028_8k.htm0001437749-26-035277
Document: 0001437749-26-035277-index-headers.html0001437749-26-035277
Document: 0001437749-26-035277-index.html0001437749-26-035277
Document: 0001437749-26-035277.txt0001437749-26-035277
8-K Data (Synthetic)0001437749-26-035277

Track record

7 reports on PHIO

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $0.8013 to $0.7710 Now $0.7520 +6.15% ▲ +3.78% +6.38% vs SPY
  2. Oct 13, 20264w ago 8-K Neutral 3/10 Entry $0.9345 to $0.8921 Now $0.7520 −19.53% ▼ −4.54% −3.39% vs SPY
  3. Sep 14, 20269w ago 8-K Bullish 5/10 Entry $1.03 to $1.01 Now $0.7520 −26.99% ▼ −1.94% −2.05% vs SPY
  4. Aug 14, 202613w ago DEFA14A Neutral 3/10 Entry $1.06 to $1.17 Now $0.7520 −29.06% ▲ +10.38% +11.57% vs SPY
  5. Apr 8, 202631w ago 8-K Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
  6. Apr 8, 202631w ago 424B5 Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
  7. Mar 5, 202636w ago 8-K Mixed 6/10 Entry $1.16 to $1.17 Now $0.7520 −35.17% ▲ +0.86% +2.39% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026